Viewing nowTelmisartan 40 mg Tablets
Telmisartan 40mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

MFDS item code 201901887 · Approved 2019.03.28 · Insurance code 694002270
Treatment of essential hypertension; reduction and prevention of cardiovascular disease risk
This medication is used for the treatment of essential hypertension. Additionally, it helps reduce the risk of developing cardiovascular diseases in high-risk patients aged 55 and older, such as those with a history of coronary artery disease, stroke, peripheral artery disease, or those with diabetes leading to end-organ damage. In particular, this medication can be used as an alternative when ACE inhibitors cannot be administered. Thus, it effectively reduces the risk of myocardial infarction, stroke, and mortality due to cardiovascular diseases, improving patients' cardiovascular health.
1. Essential hypertension Adults: Telmisartan 40 mg should be administered orally once daily with water and may be taken with or without food. A dose of 20 mg once daily may be effective for some patients. If necessary, the dose may be increased to 80 mg once daily. When increasing the dose, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. This medicine produces an additional blood pressure-lowering effect when administered with thiazide diuretics such as hydrochlorothiazide. 2. Reduction of cardiovascular risk Adults: It is recommended that 80 mg of this medicine be administered orally once daily with water; it may be taken with or without food. The effect of doses below 80 mg in reducing the risk of cardiovascular morbidity and mortality is unknown. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. ○ Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily.
This medication can cause serious harm to the fetus and newborn when taken during pregnancy; therefore, it should be discontinued immediately if pregnancy is confirmed. Pregnant or potentially pregnant women and breastfeeding women should not take this medication. Patients with severely impaired liver function or biliary excretion issues should not take this medication. Patients with hypersensitivity or a history of certain hereditary angioedema should also avoid it. Diabetic patients with moderate to severe renal impairment should not use this medication in combination with agents containing aliskiren. Elderly patients or those with hyperkalemia, as well as patients with mild to moderate hepatic impairment, should use this medication cautiously, and dosage adjustments may be necessary. Patients with heart valve disease or ischemic heart disease should be cautious while taking this medication as it may cause excessively low blood pressure, leading to serious complications. Patients with gastrointestinal disorders should be careful due to the risk of gastrointestinal bleeding. Patients with renal artery hypertension or severe renal impairment should consult a physician before use due to the risk of worsening kidney function. Regular monitoring of blood pressure, kidney function, and serum potassium levels is necessary during treatment. Caution and dosage adjustments may be required when taken with other antihypertensive medications, especially ACE inhibitors, angiotensin II receptor antagonists, and aliskiren, due to the increased risk of hypotension, hyperkalemia, and renal dysfunction. This medication is not removed by dialysis; therefore, immediate medical attention is required in case of overdose. Side effects may include dizziness, hypotension, hyperkalemia, renal failure, angioedema, liver dysfunction, interstitial pneumonia, and rhabdomyolysis, so report any unusual symptoms to healthcare professionals promptly. Dizziness or fainting may occur when driving or operating machinery, so caution is advised. This medication contains sorbitol, so patients with hereditary fructose intolerance should avoid using it. Pregnant or breastfeeding women should avoid taking this medication; if it is absolutely necessary, consultation with a physician is required. Safety and efficacy in patients under 18 years of age have not been established and are not recommended. Keep this medication out of reach of children and do not transfer it to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. It is best to maintain the storage temperature between 1°C and 30°C at room temperature.
White or almost white, double convex round tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowTelmisartan 40mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Telmisartan 40mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Telmisartan 80mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Telmisartan 40mg
Tablet · Prescription medication
Kwangdong Pharmaceutical Co., Ltd.

Telmisartan 80mg
Tablet · Prescription medication
Kwangdong Pharmaceutical Co., Ltd.

Telmisartan 40mg
Tablet · Prescription medication
Sam-il Pharmaceutical Co., Ltd.

Telmisartan 80mg
Tablet · Prescription medication
Samil Pharmaceutical Co., Ltd.

Telmisartan 80mg
Tablet · Prescription medication
Genewon Science Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.